Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason for the sharp ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

The crypto sector emerged as a top donor this election cycle, but the ads it funded weren’t about digital currencies.

Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on the stock and has a $278.00 price target ... manufacture and marketing of an insulin infusion system for people with ...

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective ... technology solutions for people living with ...

IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.

Insulet Co. (NASDAQ:PODD – Get Free Report) shares shot up 10.7% during trading on Friday after BTIG Research raised their price target on the stock from $260.00 to $270.00. BTIG Research currently ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

PARSIPPANY, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta”) (Nasdaq: EMBC), a global diabetes care company, announced it will ring the Nasdaq Closing Bell today in recognition of ...